Zimmer Biomet Holdings, Inc. vs Abbott Laboratories
A head-to-head of Zimmer Biomet Holdings, Inc. (ZBH) and Abbott Laboratories (ABT) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ZBH | ABT |
|---|---|---|
| Market Cap | $17.63B | $160.70B |
| P/E (TTM) | 25.67 | 28.20 |
| Forward P/E | 9.22 | 16.60 |
| P/S | 1.91 | 3.56 |
| P/B | 1.39 | 3.82 |
| EV/EBITDA | 8.97 | 15.88 |
| Dividend Yield | 1.07% | 2.08% |
| Profit Margin | 9.05% | 13.91% |
| Gross Margin | 69.71% | 56.42% |
| Operating Margin | 16.48% | 18.17% |
| Revenue Growth (YoY) | +9.30% | +7.78% |
| FCF Yield | 8.53% | 4.59% |
| Debt / Equity | 58.91 | 64.60 |
| Current Ratio | 1.73 | 1.39 |
Which is better: Zimmer Biomet Holdings, Inc. or Abbott Laboratories?
- ✓Larger by market cap: Abbott Laboratories
- ✓Cheaper valuation (lower P/E): Zimmer Biomet Holdings, Inc.
- ✓Higher dividend yield: Abbott Laboratories
- ✓More profitable (net margin): Abbott Laboratories
- ✓Faster revenue growth: Zimmer Biomet Holdings, Inc.
- ✓Higher free-cash-flow yield: Zimmer Biomet Holdings, Inc.
Across 13 available metrics, Zimmer Biomet Holdings, Inc. leads 10–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.